Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Compass Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 55 | 73 | +18 |
| Shares | 79.8M | 81.5M | +1.65M (+2.1%) |
| Value | $401.4M | $266.5M | −$134.9M (−33.6%) |
New holders (24)
Institutions that held Compass Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (6)
Institutions that held Compass Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Eventide Asset Management, LLC | 935,091 | $4.70M |
| Alyeska Investment Group, L.P. | 545,170 | $2.73M |
| Hudson Bay Capital Management LP | 311,500 | $1.49M |
| Silverarc Capital Management, LLC | 268,307 | $1.35M |
| Mirabella Financial Services LLP | 30,444 | $153.1K |
| Advisor Group Holdings, Inc. | 100 | $1.00K |